Literature DB >> 25173622

Idiopathic bilateral vestibulopathy: an autoimmune disease?

Antonio Greco1, Armando De Virgilio2, Andrea Gallo3, Massimo Fusconi4, Giovanni Ruoppolo5, Rosaria Turchetta6, Giulio Pagliuca7, Marco de Vincentiis8.   

Abstract

Bilateral vestibulopathy (BV) is the loss of function of both peripheral labyrinths or of the eighth nerves. Its etiology remains obscure in approximately 20% to 50% of cases (so-called idiopathic bilateral vestibulopathy, IBV). Alternatively, the cause could be viral or vascular; to date, causative gene mutations have not been identified. Other potential disease mechanisms include autoimmune disorders. Antibodies have been detected against inner ear tissue (primarily against vestibular membranous labyrinth). The data suggest that the bulk of anti-labyrinthine autoantibodies may be an epiphenomenon, but a small subgroup of organ-specific autoantibodies may synergize with a cellular response to develop vestibular lesions. The two key symptoms of BV are the following: 1. unsteadiness of gait, particularly in the dark or on uneven ground, and 2. oscillopsia associated with head movements. Episodes of vertigo are reported by patients with IBV, particularly early in the development of vestibular loss. Associated hearing loss seldom occurs in the idiopathic type of this condition. Post-mortem examinations revealed a remarkably selective loss of vestibular hair cells in the vestibular end organs but normal hair cells in the cochlea. The diagnosis is made with a simple bedside test for defective vestibular function. The diagnosis can be confirmed by bithermal caloric testing and pendular body rotation. The therapy is based on steroid treatment, and the early initiation of immunosuppression appears to be essential for therapeutic success.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmune vestibulopathy; Hearing loss; Idiopathic bilateral vestibulopathy; Labyrinths impairment; Vertigo

Mesh:

Year:  2014        PMID: 25173622     DOI: 10.1016/j.autrev.2014.08.035

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  7 in total

1.  Superficial siderosis syndrome with progressive hearing loss and bilateral vestibular failure, 51 years after a neurosurgical procedure: diagnostic value of combined MRI and video head impulse test.

Authors:  B S Aran Yoo; Jorge C Kattah
Journal:  J Neurol       Date:  2016-12-16       Impact factor: 4.849

Review 2.  Autoimmune vertigo: an update on vestibular disorders associated with autoimmune mechanisms.

Authors:  Francesca Yoshie Russo; Massimo Ralli; Daniele De Seta; Patrizia Mancini; Alessandro Lambiase; Marco Artico; Marco de Vincentiis; Antonio Greco
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

Review 3.  Audiovestibular Symptoms in Systemic Autoimmune Diseases.

Authors:  Massimo Ralli; Vittorio D'Aguanno; Arianna Di Stadio; Armando De Virgilio; Adelchi Croce; Lucia Longo; Antonio Greco; Marco de Vincentiis
Journal:  J Immunol Res       Date:  2018-08-19       Impact factor: 4.818

4.  Bilateral Vestibular Hypofunction in a Tertiary Dizziness Center: Occurrence and Etiology.

Authors:  Eleonore Josephine Pröpper; Hanna Maria Koppelaar van Eijsden; Tjard R Schermer; Tjasse Bruintjes
Journal:  J Int Adv Otol       Date:  2022-07       Impact factor: 1.316

5.  The TNFα-Transgenic Rat: Hippocampal Synaptic Integrity, Cognition, Function, and Post-Ischemic Cell Loss.

Authors:  L Creed Pettigrew; Richard J Kryscio; Christopher M Norris
Journal:  PLoS One       Date:  2016-05-04       Impact factor: 3.240

6.  Bilateral Vestibular Hypofunction: Insights in Etiologies, Clinical Subtypes, and Diagnostics.

Authors:  F Lucieer; P Vonk; N Guinand; R Stokroos; H Kingma; Raymond van de Berg
Journal:  Front Neurol       Date:  2016-03-04       Impact factor: 4.003

7.  Focused Neuro-Otological Review of Superficial Siderosis of the Central Nervous System.

Authors:  Aran Yoo; Jonathan Jou; Jeffrey D Klopfenstein; Jorge C Kattah
Journal:  Front Neurol       Date:  2018-05-28       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.